John F Mcconville, MD | |
180 Harvester Dr Ste 110, Burr Ridge, IL 60527-6686 | |
(773) 834-4064 | |
Not Available |
Full Name | John F Mcconville |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 30 Years |
Location | 180 Harvester Dr Ste 110, Burr Ridge, Illinois |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295897742 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | (Illinois) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
The University Of Chicago Medical Center | Chicago, IL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The University Of Chicago Medical Center | 7618880766 | 754 |
University Of Chicago | 7719899426 | 1137 |
News Archive
Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
The connection with the blood circulatory system is a significant step in the development of cancer. Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue.
The U.S. Food and Drug Administration today announced a proposal to ban electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior because they present an unreasonable and substantial risk to public health that cannot be corrected or eliminated through changes to the labeling.
GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.
› Verified 2 days ago
Entity Name | University Of Chicago |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
The connection with the blood circulatory system is a significant step in the development of cancer. Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue.
The U.S. Food and Drug Administration today announced a proposal to ban electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior because they present an unreasonable and substantial risk to public health that cannot be corrected or eliminated through changes to the labeling.
GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.
› Verified 2 days ago
Entity Name | The University Of Chicago Medical Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1033218128 PECOS PAC ID: 7618880766 Enrollment ID: O20031106000203 |
News Archive
Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
The connection with the blood circulatory system is a significant step in the development of cancer. Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue.
The U.S. Food and Drug Administration today announced a proposal to ban electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior because they present an unreasonable and substantial risk to public health that cannot be corrected or eliminated through changes to the labeling.
GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
John F Mcconville, MD 5841 S Maryland Ave # Mc1099, Chicago, IL 60637-1447 Ph: () - | John F Mcconville, MD 180 Harvester Dr Ste 110, Burr Ridge, IL 60527-6686 Ph: (773) 834-4064 |
News Archive
Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
The connection with the blood circulatory system is a significant step in the development of cancer. Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue.
The U.S. Food and Drug Administration today announced a proposal to ban electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior because they present an unreasonable and substantial risk to public health that cannot be corrected or eliminated through changes to the labeling.
GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.
› Verified 2 days ago
Chad T Whelan, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Dr. Vyjayanthi Atluri, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6101 S County Line Rd, Burr Ridge, IL 60527 Phone: 630-686-9000 | |
Alan R Leff, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Jayant Malhotra, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 25 Rodeo Dr, Burr Ridge, IL 60527 Phone: 630-789-6618 | |
Edgar Davila, Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 124 79th St, Burr Ridge, IL 60527 Phone: 773-641-2037 | |
William Stoecker, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Mcclintock Dr Ste 202, Burr Ridge, IL 60527 Phone: 888-220-6432 | |
Sarah H Glavin, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 |